An important component of any regulation of tobacco products the FDA issues is an economic analysis of the regulation. Models of the health-related economic costs of cigarette smoking have evolved and improved over the years, and current models take into account the complex relationship between smoking, health, and healthcare expenditures. However, there is a lack of research on healthcare costs attributable to the use of tobacco products other than cigarettes. It is important to have this information given the increased rates at which non-cigarette products are being used. To fill this gap, we propose to develop models to estimate the healthcare costs (i.e. healthcare expenditures) resulting from the use of different tobacco products, including cigars, moist snuff, chewing tobacco, menthol and nonmenthol cigarettes, combinations of these products, and secondhand smoke exposure. Specifically, we plan to use individual level data from national surveys to 1) develop microeconomic models to estimate the healthcare costs attributable to the use of different tobacco products to determine whether the kind of product substantially affects costs and 2) develop microeconomic models to estimate the healthcare costs attributable to secondhand smoke exposure. These models will allow us to evaluate the impact of potential FDA regulations on healthcare costs through the projected changes in tobacco product use and secondhand smoke exposure using three alternative approaches (time senes analysis with data from national surveys, longitudinal model analysis with the PATH data, and simulated changes in tobacco product use prevalence) and through incorporating mathematical simulation models of short-term risks of pulmonary and cardiovascular diseases. Our models will incorporate findings from other TCORS projects, including the impact of nsk perception on use of different tobacco products among young adults and older adults, and studies ofthe effects of tobacco products on lung injury and cardiovascular disease in the short-term. Having better models ofthe cost of smoking and models of costs associated with the use of other tobacco products will be useful for the regulation of tobacco products because policy analysis needs to consider the impact of regulations on tobacco consumption as well as costs.
We will develop, for the first time, estimates of the healthcare costs associated with the use of menthol cigarettes, cigars, moist snuff, and chewing tobacco as well as updated and improved estimates ofthe cost of cigarette smoking and secondhand smoke exposure. We will use an individual-level microeconomic cost model framework that improves upon the economic model used previously by the FDA. The models also can be used to evaluate the impact on healthcare expenditures of other policies that impact tobacco product use.
| Dutra, Lauren M; Glantz, Stanton A; Arrazola, René A et al. (2018) Impact of E-Cigarette Minimum Legal Sale Age Laws on Current Cigarette Smoking. J Adolesc Health 62:532-538 |
| Wang, Yingning; Sung, Hai-Yen; Lightwood, James et al. (2018) Health Care Utilization and Expenditures Attributable to Smokeless Tobacco Use Among US Adults. Nicotine Tob Res 20:1359-1368 |
| Glantz, Stanton A (2018) PMI's own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes. Tob Control 27:s9-s12 |
| St Helen, Gideon; Shahid, Marian; Chu, Sherman et al. (2018) Impact of e-liquid flavors on e-cigarette vaping behavior. Drug Alcohol Depend 189:42-48 |
| Ghosh, Arunava; Coakley, Raymond C; Mascenik, Teresa et al. (2018) Chronic E-Cigarette Exposure Alters the Human Bronchial Epithelial Proteome. Am J Respir Crit Care Med 198:67-76 |
| Glantz, Stanton A (2018) Heated tobacco products: the example of IQOS. Tob Control 27:s1-s6 |
| Yao, Tingting; Sung, Hai-Yen; Wang, Yingning et al. (2018) Healthcare Costs of Secondhand Smoke Exposure at Home for U.S. Children. Am J Prev Med : |
| Alzahrani, Talal; Pena, Ivan; Temesgen, Nardos et al. (2018) Association Between Electronic Cigarette Use and Myocardial Infarction. Am J Prev Med 55:455-461 |
| McKelvey, Karma; Popova, Lucy; Kim, Minji et al. (2018) IQOS labelling will mislead consumers. Tob Control 27:s48-s54 |
| Lempert, Lauren Kass; Glantz, Stanton A (2018) Heated tobacco product regulation under US law and the FCTC. Tob Control 27:s118-s125 |
Showing the most recent 10 out of 101 publications
